CATB up 24% @ 2.60 >> CAMBRIDGE, Mass.--(BUSINESS WIRE)--September 28, 2017--
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Company will present data from the Catabasis and Sarepta joint research collaboration in Duchenne muscular dystrophy (DMD) at the 22(nd) International Congress of the World Muscle Society in a poster presentation titled "Edasalonexent (CAT-1004), an NF-kB inhibitor, enhances myotube formation in vitro, and increases exon-skipped sarcolemmal dystrophin in muscle of mdx mice" during poster session 4 on Thursday, October 5, 2017 from 17:00 -- 18:30 CEST. The International Congress of the World Muscle Society is being held October 3 -- 7, 2017, at the Palais du Grand Large in Saint Malo, France.
Market Data 
Markets 
AI
